Shares of biotech Agenus (AGEN -3.52%)appreciated almost 5% today, after the company posted its 3rd quarter earnings. The company's key compound, QS-21 Stimulon, is licensed to some of the biggest players in the pharmaceutical space, ,including GlaxoSmithKline (GSK 1.08%) and Janssen, which is a subsidiary of Johnson & Johnson (JNJ 0.11%).
In the following video, health care analysts Max Macaluso and David Williamson discuss the company's latest quarter and a few things Agenus investors should watch.
